Lung cancer associated with an activating mutation in the 14th exon of the MET gene

Abstract

In recent years, the active search and development of new therapeutic agents for a prognostically unfavourable group of patients with disseminated non-small cell lung cancer (NSCLC) has continued. Studies show that the occurrence of lung cancer can be associated with mutations of driver genes such as EGFR, ALK, ROS1, BRAF, KRAS, RET, MET, HER2, NTRK1/2/3, etc., in the normal processes of growth, proliferation, differentiation. The discovery of targeting drugs with high activity against certain mutations has led to a paradigm opening of therapeutic approaches and continued prognosis in serious disease. The presence of activating mutations predetermines the clinical and morphological profile of the patient. One of the random mutations – MET mutation with exon 14 skipping (METex14) is observed, as a rule, in patients of older age group, with disseminated tumour process, more aggressive course of the disease and poor prognosis with chemotherapy alone. This case provides an opportunity for long-term disease control while maintaining satisfactory quality of life in an elderly patient with NSCLC associated with METex14 mutations, as well as providing a major role and method for obtaining next-generation value for personalisation of therapy and new insights into the scientific targets and the future use of molecules to them.